CN116725923A - 一种用于皮肤除皱的制剂及其制备方法、应用 - Google Patents
一种用于皮肤除皱的制剂及其制备方法、应用 Download PDFInfo
- Publication number
- CN116725923A CN116725923A CN202310845575.2A CN202310845575A CN116725923A CN 116725923 A CN116725923 A CN 116725923A CN 202310845575 A CN202310845575 A CN 202310845575A CN 116725923 A CN116725923 A CN 116725923A
- Authority
- CN
- China
- Prior art keywords
- formulation
- preparation
- skin
- percent
- stem cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000037303 wrinkles Effects 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 44
- 210000001808 exosome Anatomy 0.000 claims abstract description 31
- 210000000130 stem cell Anatomy 0.000 claims abstract description 25
- 229940072117 fennel extract Drugs 0.000 claims abstract description 24
- 241000125183 Crithmum maritimum Species 0.000 claims abstract description 20
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229940124277 aminobutyric acid Drugs 0.000 claims abstract description 15
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 15
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 15
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 15
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229940035936 ubiquinone Drugs 0.000 claims abstract description 15
- 229920001577 copolymer Polymers 0.000 claims abstract description 14
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229960005323 phenoxyethanol Drugs 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims abstract description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 7
- 150000002148 esters Chemical class 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 239000011734 sodium Substances 0.000 claims abstract description 7
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims description 56
- 238000009472 formulation Methods 0.000 claims description 54
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 239000002537 cosmetic Substances 0.000 claims description 7
- 229940047670 sodium acrylate Drugs 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 4
- 238000007664 blowing Methods 0.000 claims description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 3
- 238000002386 leaching Methods 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 3
- 150000003254 radicals Chemical class 0.000 abstract description 11
- 230000037331 wrinkle reduction Effects 0.000 abstract description 6
- 230000006872 improvement Effects 0.000 abstract description 3
- 230000009759 skin aging Effects 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 35
- 230000000694 effects Effects 0.000 description 15
- 210000002615 epidermis Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- LSQXNMXDFRRDSJ-UHFFFAOYSA-N Thymol methyl ether Chemical compound COC1=CC(C)=CC=C1C(C)C LSQXNMXDFRRDSJ-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000012496 blank sample Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- YKFLAYDHMOASIY-UHFFFAOYSA-N γ-terpinene Chemical compound CC(C)C1=CCC(C)=CC1 YKFLAYDHMOASIY-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- -1 etc. Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 210000002487 multivesicular body Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
- A61K8/355—Quinones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8152—Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
本发明提供了一种用于皮肤除皱的制剂及其制备方法、应用,涉及生物技术领域,该制剂包含以下重量份的原料:水92‑96%,丙烯酸(酯)类共聚物钠0.63‑0.72%,海茴香提取物0.05‑0.1%,泛醌0.08‑0.25%,氨基丁酸1.5‑3.5%,干细胞外泌体0.02‑0.05%,苯氧乙醇0.28‑0.35%;该制剂的自由基清除率可达76.41%,使用14天后,受试者对该制剂的细纹改善、紧致提拉和肌肤平滑评分总分分别为44、34和44,皱纹减少率达到34.12%;说明该制剂能够有效清除自由基,抑制皱纹的生长,淡化已有的皱纹,使肌肤平整度提高,延缓皮肤衰老。
Description
技术领域
本发明涉及生物技术领域,具体而言,涉及一种用于皮肤除皱的制剂及其制备方法、应用。
背景技术
随着年龄增长,作为皮肤的老化现象之一,皱纹也随之增加,但从美容等的观点出发,特别是女性、对皱纹的防止和改善的热情非常高。皱纹是指皮肤受到外界环境影响,形成游离自由基,自由基会破坏正常细胞膜组织内的胶原蛋白及活性物质,导致皮肤真皮层胶原蛋白含量逐渐减少,网状支撑体亦会变厚变硬、失去弹性,当真皮层的弹性与保水度降低时,皮肤便会失去弹性并变薄老化,表皮即形成松垮的皱纹。
皱纹渐渐出现,无论是皱纹、鱼尾纹、细纹、眼尾纹都是因为皮肤表皮层不均一的塌陷引起的。皱纹大致可分为由于包含角质层的表皮的功能降低而产生的小皱纹和由于比表皮更深的真皮的功能降低而产生的大皱纹(或表情皱纹)。由于包含角质层的表皮的功能降低而产生的皱纹,主要是由于表皮的水分保持功能受年龄增长、紫外线、低温、低湿等的影响而降低,从而产生的。另一方面,一般认为,由于真皮的功能降低而产生的皱纹,是由于基质金属蛋白酶(MMPs )受老化、紫外线、以及机械性压力的影响而发生增减,导致含有胶原蛋白、弹性蛋白( Elastin )的皮肤的弹力结构状态崩演而产生的。已经知道了,皮肤上产生的小皱纹的沟变深,会向大皱纹转变,小皱纹和大皱纹紧密相关。
在非常干澡的冬季容易产生小皱纹,这是许多人的共识,大家都认为,为了预防和改善小皱纹,用化妆品、特别是化妆水、乳液、软膏、美容液等进行保湿、并且使用加湿器进行加湿这些很重要。以保湿为目的的化妆品,特别是含有甘油、透明质酸等保湿剂的化妆品一直都在被人们使用着。
已有研究报道,干细胞培养基(CM)主要来源于间充质干细胞/间充质细胞(MSC)的培养,对皮肤有抗衰老、抗皱、抗色素沉着等有益作用。MSC培养基中的分泌物质含有可溶性蛋白和胞外囊泡。外泌体是细胞质膜和包含腔内小泡的多泡体融合而成,通过内吞途径由细胞产生。外泌体被直径为30 ~ 200 nm的脂质双层包裹,包含蛋白质、遗传物质、microRNAs (miRNAs),以及其他代谢物。干细胞外泌体强大的生物活性和细胞功能,现在被作为一种细胞治疗方案受到研究者的广泛关注。与传统护肤相比,它是直接作用于肌肤细胞,因此效果也更加明确。
发明内容
针对现有技术的不足,本发明提供了一种用于皮肤除皱的制剂及其制备方法、应用。
为了达到上述目的,本发明的技术方案是这样实现的:
一种用于皮肤除皱的制剂,该制剂包含以下重量份的原料:
水 92-96%,
丙烯酸(酯)类共聚物钠 0.63-0.72%,
海茴香提取物 0.05-0.1%,
泛醌 0.08-0.25%,
氨基丁酸 1.5-3.5%,
干细胞外泌体 0.02-0.05%,
苯氧乙醇 0.28-0.35%。
优选地,所述制剂包含以下重量份的原料:
水 94-96%,
丙烯酸(酯)类共聚物钠 0.68-0.72%,
海茴香提取物 0.08-0.1%,
泛醌 0.15-0.25%,
氨基丁酸 2.5-3.5%,
干细胞外泌体 0.03-0.05%,
苯氧乙醇 0.3-0.35%。
优选地,所述制剂包含以下重量份的原料:
水 95.53%,
丙烯酸(酯)类共聚物钠 0.72%,
海茴香提取物 0.1%,
泛醌 0.25%,
氨基丁酸 3%,
干细胞外泌体 0.05%,
苯氧乙醇 0.35%。
优选地,所述干细胞外泌体为间充质干细胞外泌体。
优选地,所述海茴香提取物的制备方法为:将海茴香自然晾干粉碎后,加入海茴香1-3倍重量的70%的乙醇水溶液,置于30-40℃下浸提5-8h,过滤得到提取液,提取液减压浓缩得到浸膏,即得。
本发明还提供了一种用于皮肤除皱的制剂的制备方法,具体包含以下步骤:
1)将水称量好,边搅拌边将丙烯酸(酯)类共聚物钠缓慢加入,待加完后搅拌至全溶;
2)边搅拌边将海茴香提取物、泛醌、氨基丁酸、干细胞外泌体和苯氧乙醇依次缓慢加入步骤1)得到的混合溶液中,混合均匀,即得。
优选地,所述干细胞外泌体的制备方法如下:
将间充质干细胞接种至MSC生长培养基培养后,4℃条件下,300×g离心10 min,去除间充质干细胞,2000×g离心10 min,去除死细胞,16000×g离心30 min,去除细胞碎片,收集上清液;于4℃条件下,140000×g离心上清液90 min,弃上清液,收集沉淀;加入PBS洗涤重悬,14000×g离心70 min,弃上清液;加入适量PBS将离心管底部的沉淀吹打混匀,0.22μm滤器过滤获得人脐带间充质干细胞的外泌体,置于-80℃保存备用。
本发明还提供了一种用于皮肤除皱的制剂在制备化妆品方面的应用。
本发明的有益效果为:
海茴香含单萜烯、伽马—松油烯、百里香酚甲醚等挥发油、果胶、维生素(尤其是维生素C)和矿物质等成分。其主要功能是抗氧化、美白祛斑,同时还能起到调节皮肤黑色素失调、提升气色、促进细胞增殖、延缓衰老、促进皮肤伤口愈合、消除痘印等功效。海茴香又叫海马齿,又叫圣彼得草,主要生长在海边的礁石上,最初是法国航海家用来晒伤的,因为海茴香中含有大量的维生素C和矿物质,所以在美容业中得到了广泛的应用。
本发明将海茴香提取物与干细胞外泌体、泛醌、氨基丁酸复配,相较于省略干细胞外泌体或省略海茴香提取物而言,复配后的制剂具有更显著的改善皮肤细纹生长,起到紧致提拉的效果,使皮肤平滑有光泽,使用14天后,受试者对细纹改善、紧致提拉和肌肤平滑评分总分分别为44、34和44,皱纹减少率达到34.12%,且该制剂在清除自由基的方面表现出优异的能力,自由基清除率可达76.41%。
附图说明
图1:制剂1的除皱功效使用感评分。
图2:制剂2的除皱功效使用感评分。
图3:制剂3的除皱功效使用感评分。
图4:制剂4的除皱功效使用感评分。
图5:制剂5的除皱功效使用感评分。
图6:制剂6的除皱功效使用感评分。
图7:制剂7的除皱功效使用感评分。
图8:制剂8的除皱功效使用感评分。
图9:制剂9的除皱功效使用感评分。
具体实施方式
以下通过特定的具体实例说明本发明的实施方式,本领域技术人员可由本说明书所揭露的内容轻易地了解本发明的其他优点与功效。本发明还可以通过另外不同的具体实施方式加以实施或应用,本说明书中的各项细节也可以基于不同观点与应用,在没有背离本发明的精神下进行各种修饰或改变。需说明的是,在不冲突的情况下,以下实施例及实施例中的特征可以相互组合。
实施例
将间充质干细胞接种至MSC生长培养基进行培养,每隔2-3天换液,当细胞浓度融合至80-90%时,用胰蛋白酶消化后传代培养,当传代后的培养基细胞融合至80-90%,将细胞培养液于4℃条件下,300×g离心10 min,去除间充质干细胞,2000×g离心10 min,去除死细胞,16000×g离心30 min,去除细胞碎片,收集上清液;于4℃条件下,140000×g离心上清液90 min,弃上清液,收集沉淀;加入PBS洗涤重悬,14000×g离心70 min,弃上清液;加入适量PBS将离心管底部的沉淀吹打混匀,0.22μm滤器过滤获得人脐带间充质干细胞的外泌体,置于-80℃保存备用。
将海茴香自然晾干粉碎后,加入海茴香1-3倍重量的70%的乙醇水溶液,置于30-40℃下浸提5-8h,过滤得到提取液,提取液减压浓缩得到浸膏,即得海茴香提取物。
将水称量好,边搅拌边将丙烯酸(酯)类共聚物钠缓慢加入,待加完后搅拌至全溶;边搅拌边将海茴香提取物、泛醌、氨基丁酸、干细胞外泌体和苯氧乙醇依次缓慢加入步骤1)得到的混合溶液中,混合均匀,即得。
各制剂的成分配比按照表1所示进行称量。
表1:各制剂的成分配比(重量百分比)
水 | 丙烯酸(酯)类共聚物钠 | 海茴香提取物 | 泛醌 | 氨基丁酸 | 干细胞外泌体 | 苯氧乙醇 | |
制剂1 | 95.53 | 0.72 | 0.10 | 0.25 | 3.00 | 0.05 | 0.35 |
制剂2 | 95.17 | 0.72 | 0.50 | 0.25 | 3.00 | 0.01 | 0.35 |
制剂3 | 95.58 | 0.72 | 0.05 | 0.25 | 3.00 | 0.05 | 0.35 |
制剂4 | 95.63 | 0.72 | 0 | 0.25 | 3.00 | 0.05 | 0.35 |
制剂5 | 95.58 | 0.72 | 0.10 | 0.25 | 3.00 | 0 | 0.35 |
制剂6 | 95.78 | 0.72 | 0.10 | 0 | 3.00 | 0.05 | 0.35 |
制剂7 | 98.53 | 0.72 | 0.10 | 0.25 | 0 | 0.05 | 0.35 |
制剂8 | 98.78 | 0.72 | 0.10 | 0 | 0 | 0.05 | 0.35 |
制剂9 | 95.68 | 0.72 | 0 | 0.25 | 3.00 | 0 | 0.35 |
1、除皱功效使用感评分
测试人群:年龄:20-60岁之间,无过敏历史、有护肤品使用经验的试用者90名,每组10名试用者,分别试用制剂1-9,每天早晚各使用一次,每次使用量为2 mL,涂抹于脸部。
测试方法:请试用者依使用时长(0,7,14 天),根据试用结果打分。
问卷题目:使用产品后,细纹改善;紧致拉提;肌肤平滑的效果评分。
评分标准:5分,非常显着;3分,普通;1分,无效果。
取试用者的打分结果,将每组内每个评分项的10名试用者打分相加得到总分,总分越高,则效果越好,最终得到如图1-9所示的评价结果。
从图1可以看出,受试者对制剂1的除皱效果给予高度评价,使用14天后,对制剂1的细纹改善、紧致提拉和肌肤平滑评分总分分别为44、34和44,人均评分分别为4.4、3.4和4.4,说明制剂1能够显著控制皱纹生长,并淡化已有的细纹,提拉松弛的表皮,且受试者均未反应有过敏、不适现象。
从图2-9可以看出,海茴香提取物与干细胞外泌体、泛醌、氨基丁酸复配,相较于省略干细胞外泌体(制剂5)或省略海茴香提取物(制剂4)而言,制剂1具有更显著的细纹改善作用,且泛醌、氨基丁酸的加入促进了皮肤对海茴香提取物和干细胞外泌体的吸收,省略制剂中的任意功功效组分或调整功效成分均会导致皮肤的细纹改善、紧致拉提和平滑效果减弱。
2、紧致功效定量分析
VISIA皮肤检测仪是一种能对皮肤的特征进行定量分析的仪器。Visia皮肤检测仪能对皮肤/>、毛孔、皱纹、/>、/>、/>斑和日光损伤定量评估。于使用第0、14天分别使用VISIA皮肤测试仪测试每位受试者面部皮肤情况,并对皱纹情况准确记录和计数,每组十名受试者测试结果取平均值得到皱纹定量测试结果如表2。
自由基清除率(%)=(空白对照-样品)/空白对照×100%
表2:各制剂的皱纹减少情况
第0天 | 第14天 | 减少率(%) | |
制剂1 | 15.33 | 10.10 | 34.12 |
制剂2 | 13.67 | 10.76 | 21.29 |
制剂3 | 14.34 | 11.17 | 22.11 |
制剂4 | 14.56 | 12.63 | 13.26 |
制剂5 | 16.43 | 14.39 | 12.42 |
制剂6 | 14.87 | 12.40 | 16.61 |
制剂7 | 15.26 | 13.46 | 11.80 |
制剂8 | 15.77 | 13.83 | 12.30 |
制剂9 | 16.08 | 14.72 | 8.46 |
制剂1的细纹改善效果显著,使用14天的皱纹减少率达到34.12%,而制剂2-3的皱纹减少率仅为21.29%、和22.11,说明各个组分的用量影响了制剂的紧致效果,只有特定的用量比例才能实现最佳的紧致效果,且省略组分中任意一个或多个组分均会导致制剂的皱纹减少率下降。
3、DPPH自由基清除效果
将DPPH试药溶解于DMSO配置为0.25mM DPPH溶液,取 DPPH溶液100μL和各样品100μL依次加入到96孔板中,暗处静置30min,490nm处测定其吸光度,以未添加样品的作为空白对照,进行10次平行实验,测试结果如表3所示。
自由基清除率(%)=(空白对照-样品)/空白对照×100%
表3:各制剂的自由基清除率
自由基清除率(%) | |
制剂1 | 76.41 |
制剂2 | 51.03 |
制剂3 | 54.60 |
制剂4 | 29.47 |
制剂5 | 26.23 |
制剂6 | 32.75 |
制剂7 | 31.53 |
制剂8 | 20.62 |
制剂9 | 11.44 |
从表3可以看出,功效成分海茴香提取物与干细胞外泌体、泛醌、氨基丁酸的组合能够有效清除自由基,制剂1的清除率达76.41%,说明其具有除皱皮肤的功效,能够改善细纹生长,而不含干细胞外泌体的制剂5,自由基清除率仅有26.23%,不含海茴香提取物的制剂4,自由基清除率仅有29.47%,效果明显均劣于制剂1,说明海茴香提取物与干细胞外泌体具有协同增效的作用。
综上所述,本发明的用于皮肤除皱的制剂能够有效清除自由基,抑制皱纹的生长,淡化已有的皱纹,使肌肤平整度提高,长期使用可使皮肤平滑有光泽,延缓皮肤衰老。
以上各实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述各实施例对本发明进行了详细的说明,但本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分或者全部技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的范围。
Claims (8)
1.一种用于皮肤除皱的制剂,其特征在于,所述制剂包含以下重量份的原料:
水 92-96%,
丙烯酸(酯)类共聚物钠 0.63-0.72%,
海茴香提取物 0.05-0.1%,
泛醌 0.08-0.25%,
氨基丁酸 1.5-3.5%,
干细胞外泌体 0.02-0.05%,
苯氧乙醇 0.28-0.35%。
2.如权利要求1所述的用于皮肤除皱的制剂,其特征在于,所述制剂包含以下重量份的原料:
水 94-96%,
丙烯酸(酯)类共聚物钠 0.68-0.72%,
海茴香提取物 0.08-0.1%,
泛醌 0.15-0.25%,
氨基丁酸 2.5-3.5%,
干细胞外泌体 0.03-0.05%,
苯氧乙醇 0.3-0.35%。
3.如权利要求2所述的用于皮肤除皱的制剂,其特征在于,所述制剂包含以下重量份的原料:
水 95.53%,
丙烯酸(酯)类共聚物钠 0.72%,
海茴香提取物 0.1%,
泛醌 0.25%,
氨基丁酸 3%,
干细胞外泌体 0.05%,
苯氧乙醇 0.35%。
4.如权利要求1-3任一所述的用于皮肤除皱的制剂,其特征在于,所述干细胞外泌体为间充质干细胞外泌体。
5.如权利要求1-3任一项所述的用于皮肤除皱的制剂,其特征在于,所述海茴香提取物的制备方法为:将海茴香自然晾干粉碎后,加入海茴香1-3倍重量的70%的乙醇水溶液,置于30-40℃下浸提5-8h,过滤得到提取液,提取液减压浓缩得到浸膏,即得。
6.权利要求1-5任一项所述的一种用于皮肤除皱的制剂的制备方法,其特征在于,具体包含以下步骤:
1)将水称量好,边搅拌边将丙烯酸(酯)类共聚物钠缓慢加入,待加完后搅拌至全溶;
2)边搅拌边将海茴香提取物、泛醌、氨基丁酸、干细胞外泌体和苯氧乙醇依次缓慢加入步骤1)得到的混合溶液中,混合均匀,即得。
7.如权利要求6所述的一种用于皮肤除皱的制剂的制备方法,其特征在于,所述干细胞外泌体的制备方法如下:
将间充质干细胞接种至MSC生长培养基培养后,4℃条件下,300×g离心10 min,去除间充质干细胞,2000×g离心10 min,去除死细胞,16000×g离心30 min,去除细胞碎片,收集上清液;于4℃条件下,140000×g离心上清液90 min,弃上清液,收集沉淀;加入PBS洗涤重悬,14000×g离心70 min,弃上清液;加入适量PBS将离心管底部的沉淀吹打混匀,0.22μm滤器过滤获得人脐带间充质干细胞的外泌体,置于-80℃保存备用。
8.权利要求1-5任一所述的一种用于皮肤除皱的制剂在制备化妆品方面的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310845575.2A CN116725923A (zh) | 2023-07-11 | 2023-07-11 | 一种用于皮肤除皱的制剂及其制备方法、应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310845575.2A CN116725923A (zh) | 2023-07-11 | 2023-07-11 | 一种用于皮肤除皱的制剂及其制备方法、应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116725923A true CN116725923A (zh) | 2023-09-12 |
Family
ID=87915099
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310845575.2A Pending CN116725923A (zh) | 2023-07-11 | 2023-07-11 | 一种用于皮肤除皱的制剂及其制备方法、应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116725923A (zh) |
-
2023
- 2023-07-11 CN CN202310845575.2A patent/CN116725923A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2689767B1 (en) | Methods for improving the condition and appearance of skin | |
EP3058938B1 (en) | Plant composition having moisturizing, anti-wrinkle, and anti-allergic efficacies, and preparation method thereof | |
KR102265730B1 (ko) | 피부 주름 개선 및 미백용 화장료 조성물 | |
TWI693899B (zh) | 石榴發酵物及其用途 | |
JP5940986B2 (ja) | 美容的処置のためのハエジゴクの抽出物を含有する組成物 | |
US20130101689A1 (en) | Composition containing paper mulberry extracts | |
CN108379110B (zh) | 护肤组合物、护肤膏霜及其制备方法 | |
JP2013502380A (ja) | 皮膚清澄複合体、前記複合体の使用、前記複合体を含む化粧又は医薬組成物及びその適用のための方法 | |
KR20140060928A (ko) | 티오레독신을 함유하는 피부 외용제 조성물 | |
CN114533618A (zh) | 一种美白修复组合物及其制备方法和应用 | |
CN113876665A (zh) | 一种具有抗皱功效的面霜组合物及其制备方法和应用 | |
CN113384482A (zh) | 一种保湿嫩肤精华露及其制备方法 | |
CN112891243A (zh) | 一种含抗皱功效组合物的化妆品及其制备方法 | |
CN112386627A (zh) | 迷迭香愈伤组织汁液的用途以及用以诱导迷迭香愈伤组织的培养基 | |
CN114099388B (zh) | 一种抗皱组合物其制备方法及其应用 | |
US20190343746A1 (en) | Cosmetic composition including gamma-pga as active ingredient | |
CN113730330B (zh) | 一种具有祛黑眼圈功效的眼霜组合物及其制备方法 | |
CN116725923A (zh) | 一种用于皮肤除皱的制剂及其制备方法、应用 | |
CN113171316B (zh) | 一种修复、缓解皮肤刺激化妆品及制备方法 | |
US11123386B2 (en) | Fermentation product of Punica granatum and uses thereof | |
CN111166688A (zh) | 青蒿烯作为保湿抗皱、抗衰老成分在化妆品中的应用 | |
CN111544335A (zh) | 一种含可溶性胶原和孔雀石提取物的精华及制备方法 | |
KR20120058718A (ko) | 황숙종 인삼 추출물을 함유하는 피부 외용제 조성물 | |
CN116869911A (zh) | 一种用于皮肤紧致的制剂及其制备方法、应用 | |
TWI743393B (zh) | 白鶴靈芝癒傷組織的萃取物用於促進膠原蛋白增生的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |